Global Migraine Drugs Market (By Drugs - Triptan, CGRP, Acetylcholine Inhibitors/ Neurotoxins & Others; Nations-The US, the UK, Germany, France, Italy, Spain and Japan) - Outlook 2025
INDUSTRY INSIGHTS
According to a new report by Rockville Research, the global migraine therapeutics market is estimated to be valued at US$ 7 billion in the year 2025, growing at a CAGR of 15.2% in the period 2019 to 2025. Growth of the market is driven by factors such as increasing incidences of migraine, rising female population, patent expiration and stressed lifestyle.
Migraine is a complex debilitating neurological disorder which is often characterized by recurrent severe headaches in one side of the head. It is generally preceded by sensory warning signs and other symptoms such as sensitivity to light and noise, nausea, vomiting, dizziness, etc.
Migraine therapeutics market is expected to witness advent of first in-class novel migraine drugs especially meant for patients unresponsive to triptans or ones at risk of cardiovascular disorders. Allergan’s ubrogepant and Eli Lilly’s Lasmiditan are one of the leading migraine drugs based on novel mechanism of action.
REPORT SCOPE
This report “Global Migraine Therapeutics Market [By Drug Classes - Triptan, CGRP, Acetylcholine Inhibitors/Neurotoxins, Others; By Region – North America (The US), Europe (The UK, Germany, France, Italy & Spain) and Asia Pacific (Japan) - Outlook 2025]” provides a detailed analysis of the global migraine therapeutics market from qualitative and quantitative outlooks during the forecast period across various therapeutic classes. It also provides coverage on market dynamics with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.
Parameter Description
The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, Rockville Research has segmented global migraine therapeutics market report has been segmented on the basis of drug classes and region:-
Therapeutic Class Outlook, Revenue (2017 – 2025E, US$ Billions)
We provide customization of the study in order to provide specific information as sought by the client.
According to a new report by Rockville Research, the global migraine therapeutics market is estimated to be valued at US$ 7 billion in the year 2025, growing at a CAGR of 15.2% in the period 2019 to 2025. Growth of the market is driven by factors such as increasing incidences of migraine, rising female population, patent expiration and stressed lifestyle.
Migraine is a complex debilitating neurological disorder which is often characterized by recurrent severe headaches in one side of the head. It is generally preceded by sensory warning signs and other symptoms such as sensitivity to light and noise, nausea, vomiting, dizziness, etc.
Migraine therapeutics market is expected to witness advent of first in-class novel migraine drugs especially meant for patients unresponsive to triptans or ones at risk of cardiovascular disorders. Allergan’s ubrogepant and Eli Lilly’s Lasmiditan are one of the leading migraine drugs based on novel mechanism of action.
REPORT SCOPE
This report “Global Migraine Therapeutics Market [By Drug Classes - Triptan, CGRP, Acetylcholine Inhibitors/Neurotoxins, Others; By Region – North America (The US), Europe (The UK, Germany, France, Italy & Spain) and Asia Pacific (Japan) - Outlook 2025]” provides a detailed analysis of the global migraine therapeutics market from qualitative and quantitative outlooks during the forecast period across various therapeutic classes. It also provides coverage on market dynamics with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.
Parameter Description
- Base year 2009
- Forecast period 2019 - 2025
- Market sizing Revenue in US$ Billions & CAGR for the period 2019 to 2025
- Country coverage G7 Nations - The US, The UK, Germany, France, Italy, Spain & Japan
- Vendor scope Eli Lilly & Company, Teva Pharmaceutical Industries, Alder Biopharmaceuticals, Amgen Inc., AbbVie Inc. & Pfizer Inc.
- Report coverage Revenue forecast, market share analysis, company analysis, competitive landscape, market growth drivers, market restraints, market trends and company profiles
The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, Rockville Research has segmented global migraine therapeutics market report has been segmented on the basis of drug classes and region:-
Therapeutic Class Outlook, Revenue (2017 – 2025E, US$ Billions)
- Triptan
- CGRP
- Acetylcholine Inhibitors/Neurotoxins
- Others
- North America
- Europe
- Asia Pacific
- The US
- The UK
- Germany
- France
- Italy
- Spain
- Japan
- Eli Lilly & Company
- Teva Pharmaceutical Industries
- Alder Biopharmaceuticals
- Amgen Inc.
- AbbVie Inc.
- Pfizer Inc.
- Migraine Drug Manufacturers
- Chemical Suppliers
- End Users
- Research Professionals
- Healthcare Consultancies
- Regulatory Bodies
- Historical market size of migraine therapeutics from 2009 to 2018 in US$ Billions.
- Projected market growth in the forecasted period 2019 to 2025 with estimated revenue for each year in US$ Billions.
- Revenue forecasts of major migraine therapeutics in the period 2016 to 2025 in US$ Billions.
- Regional and country of migraine therapeutics in the period 2017 to 2025 in US$ Billions.
- Market drivers, restraints and industry trends that has impact on revenue.
- Profiling of major companies with detailed analysis of major migraine therapeutics approved for marketing as well as in pipeline.
We provide customization of the study in order to provide specific information as sought by the client.
1. EXECUTIVE SUMMARY
2. RESEARCH METHODOLOGY
3. MIGRAINE
3.1 Overview
3.1.1 Types of Migraine
3.1.2 Stages of Migraine
3.1.3 Symptoms of Migraine
3.1.4 Diagnosis
3.2 Treatment
3.2.1 Abortive Medications
3.2.2 Preventive Medications
3.2.3 Alternative Medicine
4. MARKET ANALYSIS
4.1.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Treatment Drugs
4.2.2 Market Share by Drug Type
4.2.3 Market Share by Nations
5. MARKET SEGMENTATION BY DRUG CLASS
5.1 Triptan
5.1.1 Overview
5.1.2 Market Sizing (Actual & Forecasted)
5.2 CGRP
5.2.1 Overview
5.2.2 Market Sizing (Actual & Forecasted)
5.3 Acetylcholine Inhibitors/ Neurotoxins
5.3.1 Overview
5.3.2 Market Sizing (Actual & Forecasted)
5.4 Others
5.4.1 Overview
5.4.2 Market Sizing (Actual & Forecasted)
6. MIGRAINE MARKET REGIONAL ANALYSIS
6.1 North America
6.1.1 The US
6.1.1.1 Market Sizing (Actual & Forecasted)
6.2 Europe
6.2.1 France
6.2.1.1 Market Sizing (Actual & Forecasted)
6.2.2 Germany
6.2.2.1 Market Sizing (Actual & Forecasted)
6.2.3 Italy
6.2.3.1 Market Sizing (Actual & Forecasted)
6.2.4 Spain
6.2.4.1 Market Sizing (Actual & Forecasted)
6.2.5 The UK
6.2.5.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Japan
6.3.1.1 Market Sizing (Actual & Forecasted)
7. MARKET DYNAMICS
7.1 Industry Trends & Development
7.1.1 Anti-CGRP Drugs Pipeline
7.1.2 Launch of Cheaper Migraine Drugs
7.1.3 Emphasis on Preventative Migraine Treatment
7.1.4 Advent of Novel Migraine Drugs
7.1.5 Neuromodulation Devices for Migraine Treatment
7.2 Growth Drivers
7.2.1 Prevalence of Migraine
7.2.2 Rising Female Population
7.2.3 Patent Expirations
7.2.4 Stressed Lifestyle
7.3 Challenges
7.3.1 Poor Efficacy of Drugs
7.3.2 Regulatory Hurdle
7.3.3 Low Diagnosis Rate
7.3.4 Preference for Alternative Therapies
8. COMPETITIVE LANDSCAPE
9. COMPANY PROFILE
9.1 Eli Lilly & Company
9.2 Teva Pharmaceutical Industries
9.3 Alder Biopharmaceuticals
9.4 Amgen Inc.
9.5 AbbVie Inc.
9.6 Pfizer Inc.
2. RESEARCH METHODOLOGY
3. MIGRAINE
3.1 Overview
3.1.1 Types of Migraine
3.1.2 Stages of Migraine
3.1.3 Symptoms of Migraine
3.1.4 Diagnosis
3.2 Treatment
3.2.1 Abortive Medications
3.2.2 Preventive Medications
3.2.3 Alternative Medicine
4. MARKET ANALYSIS
4.1.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Treatment Drugs
4.2.2 Market Share by Drug Type
4.2.3 Market Share by Nations
5. MARKET SEGMENTATION BY DRUG CLASS
5.1 Triptan
5.1.1 Overview
5.1.2 Market Sizing (Actual & Forecasted)
5.2 CGRP
5.2.1 Overview
5.2.2 Market Sizing (Actual & Forecasted)
5.3 Acetylcholine Inhibitors/ Neurotoxins
5.3.1 Overview
5.3.2 Market Sizing (Actual & Forecasted)
5.4 Others
5.4.1 Overview
5.4.2 Market Sizing (Actual & Forecasted)
6. MIGRAINE MARKET REGIONAL ANALYSIS
6.1 North America
6.1.1 The US
6.1.1.1 Market Sizing (Actual & Forecasted)
6.2 Europe
6.2.1 France
6.2.1.1 Market Sizing (Actual & Forecasted)
6.2.2 Germany
6.2.2.1 Market Sizing (Actual & Forecasted)
6.2.3 Italy
6.2.3.1 Market Sizing (Actual & Forecasted)
6.2.4 Spain
6.2.4.1 Market Sizing (Actual & Forecasted)
6.2.5 The UK
6.2.5.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Japan
6.3.1.1 Market Sizing (Actual & Forecasted)
7. MARKET DYNAMICS
7.1 Industry Trends & Development
7.1.1 Anti-CGRP Drugs Pipeline
7.1.2 Launch of Cheaper Migraine Drugs
7.1.3 Emphasis on Preventative Migraine Treatment
7.1.4 Advent of Novel Migraine Drugs
7.1.5 Neuromodulation Devices for Migraine Treatment
7.2 Growth Drivers
7.2.1 Prevalence of Migraine
7.2.2 Rising Female Population
7.2.3 Patent Expirations
7.2.4 Stressed Lifestyle
7.3 Challenges
7.3.1 Poor Efficacy of Drugs
7.3.2 Regulatory Hurdle
7.3.3 Low Diagnosis Rate
7.3.4 Preference for Alternative Therapies
8. COMPETITIVE LANDSCAPE
9. COMPANY PROFILE
9.1 Eli Lilly & Company
9.2 Teva Pharmaceutical Industries
9.3 Alder Biopharmaceuticals
9.4 Amgen Inc.
9.5 AbbVie Inc.
9.6 Pfizer Inc.
